Effects of Omacor and Aspirin on Platelet Function

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Omacor (now Lovaza) is a pharmaceutical omega-3 fatty acid product. Omega-3 fatty acids can affect blood clotting by altering the function of the blood platelets. Aspirin can do the same. The purpose of this study is to determine the individual and combined effects of these two agents on platelet function using a whole blood method.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sanford Research
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Subjects may be male or female and between the ages of 21 and 60,

• Non-smokers,

• Taking no medications, vitamin pills, nutritional supplements or herbal preparations.

Exclusion Criteria:

• Subjects may not have a history of allergic reactions to aspirin, fish or fish oils.

• Birth control pills are not allowed.

• Subject cannot have an allergy to aspirin or to non-steroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, others), naproxen (Aleve, Naprosyn, Anaprox, others), indomethacin (Indocin), or ketoprofen (Orudis KT, Orudis, Oruvail), nabumetone (Relafen), oxaprozin (Daypro), or tartrazine.

• Drinking more than three alcoholic beverages a day

• Having any of the following conditions:

• an ulcer or bleeding in the stomach,

• liver or kidney disease,

• bleeding or blood clotting disorder (e.g., hemophilia),

• congestive heart failure,

• fluid retention,

• heart disease,

• high blood pressure,

• gout,

• asthma,

• arthritis, or

• nasal polyps.